Namodenoson study for severe fatty liver disease cleared for US
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
Fatty liver disease
Intermittent fasting protects against fatty liver disease in mouse models
An intermittent fasting regimen reduced liver fat buildup and lowered the likelihood of liver cancer in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), a severe…
GPR75 protein may be fatty liver disease therapeutic target: Study
Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…
US government to launch 1st study of disease prevalence in MASLD
The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…
FXR314 well tolerated, lowers liver fat, Phase 2 MASH trial shows
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…
Madrigal CEO: Rezdiffra OK for NASH a ‘watershed moment’
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…
Fatty liver disease treatment DD01 gets FDA fast track designation
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DD01 as a potential treatment for a severe manifestation of fatty…
Chiglitazar lowers MASH patients’ liver fat accumulation: Phase 2 trial
Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…
Severe fatty liver disease patients see benefits with lanifibranor
Inventiva’s investigational oral therapy lanifibranor safely reduced blood sugar levels and eased signs of liver disease among people with metabolic dysfunction-associated steatohepatitis (MASH), a…
Fish defense mechanism may reveal fatty liver disease therapeutic target
A possible therapeutic target for fatty liver disease (FLD) has been identified by researchers studying the natural defense mechanisms of certain cave-dwelling fish. While…
